Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for POINT Biopharma Global Inc. (PNT : NSDQ)
 
 • Company Description   
POINT Biopharma Global Inc. is a radiopharmaceutical company. It builds a platform for the clinical development and commercialization of radioligands which fight cancer. POINT Biopharma Global Inc., formerly known as Research Alliance Corp., is based in INDIANAPOLIS.

Number of Employees: 72

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.51 Daily Weekly Monthly
20 Day Moving Average: 278,628 shares
Shares Outstanding: 90.12 (millions)
Market Capitalization: $586.71 (millions)
Beta: -0.39
52 Week High: $11.72
52 Week Low: $4.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.77% -16.53%
12 Week -4.12% 7.75%
Year To Date 16.25% 42.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4850 WEST 78TH STREET
-
INDIANAPOLIS,IN 46268
USA
ph: 64-7812-2417
fax: -
None http://www.pointbiopharma.com
 
 • General Corporate Information   
Officers
Joe McCann - Chief Executive Officer and Director
Allan C. Silber - Executive Chair and Director
Bill Demers - Chief Financial Officer
Rajesh K. Malik - Director
Jonathan Ross Goodman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 730541109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 90.12
Most Recent Split Date: (:1)
Beta: -0.39
Market Capitalization: $586.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -21.54
12/31/21 - -22.54
09/30/21 - -
ROA
03/31/22 - -20.72
12/31/21 - -18.84
09/30/21 - -
Current Ratio
03/31/22 - 17.05
12/31/21 - 30.56
09/30/21 - 32.03
Quick Ratio
03/31/22 - 17.05
12/31/21 - 30.56
09/30/21 - 32.04
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.65
12/31/21 - 2.83
09/30/21 - 2.99
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©